While Zepbound is not FDA-approved specifically for fatty liver disease, emerging clinical evidence suggests potential hepatic benefits
Clinical Tips Start low, go slow: Use every other night, increasing to nightly as tolerated
Watch-outs to know: Some experts have concerns that TA-1 could aggravate an autoimmune disorder, and while the reported side effects in clinical settings are mild, health experts are wary about the unofficial use of TA-1
The Trump administration faces an arduous task of encouraging states to expand Medicaid coverage of expensive anti-obesity drugs as governments face strained budgets and sweeping federal cuts in the presidents tax-and-spending law
The effects of tirzepatide on the body share many similarities with semaglutide
The semaglutide cohort ( n = 1470) compared with the naltrexone/topiramate cohort ( n = 1430) was older, included more women, had a higher prevalence of severe obesity and obesity-associated comorbidities including T2DM and lower prevalence of adverse socioeconomic determinants of health, problems with lifestyle, and substance use disorders